'Er niacin' presentation slideshows

Er niacin - PowerPoint PPT Presentation

Emerging targets in HDL modification: Relevant data from development programs

Emerging targets in HDL modification: Relevant data from development programs

Emerging targets in HDL modification: Relevant data from development programs. Prof. John Kastelein Academic Medical Centre Amsterdam, The Netherlands. Novel Approaches to Modify Lipids and Lipoproteins. Low Density Lipoprotein High Density Lipoprotein Triglyceride Rich Lipoproteins

★ ★ ★ ★ ★

473 views • 38 slides
Emerging targets in HDL modification: Relevant data from development programs

Emerging targets in HDL modification: Relevant data from development programs

Emerging targets in HDL modification: Relevant data from development programs. Prof. John Kastelein Academic Medical Centre Amsterdam, The Netherlands. Novel Approaches to Modify Lipids and Lipoproteins. Low Density Lipoprotein High Density Lipoprotein Triglyceride Rich Lipoproteins

★ ★ ★ ★ ★

549 views • 38 slides
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease.

★ ★ ★ ★ ★

366 views • 29 slides
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease.

★ ★ ★ ★ ★

348 views • 29 slides
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease.

★ ★ ★ ★ ★

306 views • 24 slides
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease.

★ ★ ★ ★ ★

325 views • 24 slides
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease.

★ ★ ★ ★ ★

339 views • 24 slides
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease.

★ ★ ★ ★ ★

246 views • 24 slides

View Er niacin PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Er niacin PowerPoint presentations. You can view or download Er niacin presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.